Nan Zhu PhD

Publications

• Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays.

  (Deshpande A, Chen BR, Zhao L, Saddoris K, Kerr M, Zhu N, Mali P, Deshpande AJ.) J Vis Exp. 2019 Jan 07(143).

• PLCγ-dependent mTOR signalling controls IL-7-mediated early B cell development.

  (Yu M, Chen Y, Zeng H, Zheng Y, Fu G, Zhu W, Broeckel U, Aggarwal P, Turner A, Neale G, Guy C, Zhu N, Chi H, Wen R, Wang D.) Nat Commun. 2017 11 13;8(1):1457.

• Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.

  (Olp MD, Zhu N, Smith BC.) Biochemistry. 2017 10 17;56(41):5485-5495.

• Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.

  (Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T.) Cell Rep. 2016 Mar 01;14(8):1953-65.

• DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.

  (Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA.) Nat Med. 2015 Apr;21(4):335-43.

• AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.

  (Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA.) Cancer Cell. 2014 Dec 08;26(6):896-908.

• CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

  (Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW.) Genes Dev. 2014 Aug 15;28(16):1800-14.

• Notch pathway activation targets AML-initiating cell homeostasis and differentiation.

  (Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY, Aifantis I.) J Exp Med. 2013 Feb 11;210(2):301-19.

• STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

  (Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T.) Cancer Res. 2013 Jan 01;73(1):373-84.

• Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

  (Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.) Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33.

• Chromatin-modifying enzymes as modulators of reprogramming.

  (Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ.) Nature. 2012 Mar 04;483(7391):598-602.

• Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains.

  (Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH.) Genes Dev. 2012 Feb 15;26(4):344-9.